CRON · NASDAQ · Drug Manufacturers - Specialty & Generic

Cronos Group (CRON)

Branded cannabis portfolio across Canada, Israel, and other international markets.

$3.41
vs last close−0.02 (−0.73%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue252425283430323336914571
Cost of revenue212221213119191918752642
Gross profit4246411141518161828
26242022372218201992021
Research & development111111111111
221816192121161717141718
Selling & marketing565466555767
General & administrative16121115151411121271211
Other expenses3432150121−612
Operating income−22−22−16−16−34−11−4−5−17−17
19−24135385711−3428−191928
Interest income131414131212109121099
Other non-operating income−1−3−2−1−142−1−1−28430−28
Income before tax−3−46−3−115467−3927−121836
Income tax expense−10−1−2−320−1−1−1220
Net income from continuing operations−2−45−2−97448−382801536
Discontinued operations000000000000
Net income−2−45−2−98446−4026−21432
EPS, basic−$0.00−$0.12−$0.01−$0.02$0.02$0.12$0.02−$0.10$0.07−$0.00$0.04$0.08
EPS, diluted−$0.00−$0.12−$0.01−$0.02$0.02$0.11$0.02−$0.10$0.07−$0.00$0.04$0.08
Weighted average shares, basic381381381382382382383385385385385385
Weighted average shares, diluted381381381382386387387385385385385385
EBITDA−18−17−12−14−16−11−1031−45236
Depreciation & amortization212242344−840
EBIT−20−18−14−15−19−13−4−527−36−136